SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17...
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
